Ellen Smith received a death sentence for her advanced lung cancer five years ago, but it was commuted by a revolution in human genetics, drug therapies and clinical approaches unfolding at the University of Colorado Hospital.
The advances have saved her life, by her reckoning, four times.
The accelerating speed of DNA sequencing, drug development and data analysis has led UCHealth, the University of Colorado Medical School and Children's Hospital Colorado to join in an effort to fundamentally change the way they care for patients.
The partnership will invest more than $63 million over the next five years to create a new division, adding clinicians, genetic counselors, researchers and advanced practice nurses — and also expanding a DNA bank and advanced data warehouse. It's called the Center for Personalized Medicine and Biomedical Informatics.
Read the complete story at: http://bit.ly/1nmMyn8
Source: The Denver Post
Pembrolizumab Receives Full Approval for Select Patients With MSI-H or dMMR Solid Tumors
March 29th 2023The FDA has granted full approval to pembrolizumab for the treatment of some patients with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors that have progressed following previous treatment.
Read More
The FDA wants to discourage the use of single-arm trials for accelerated approvals of oncology drugs; Cigna’s review system allows doctors to reject claims without reading them, an investigation shows; US bishops want to restrict gender transition care in Catholic hospitals.
Read More
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
February 3rd 2022On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.
Listen
Osimertinib Demonstrates Overall Survival Benefit as Adjuvant Lung Cancer Treatment
March 19th 2023Osimertinib (Tagrisso; AstraZeneca) now has shown a statistically significant and clinically meaningful overall survival benefit in both the early adjuvant and late-stage metastatic settings.
Read More
2 Clarke Drive
Cranbury, NJ 08512